AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma
Gantke et al.
ASCO 2017 AFM26
Gantke et al.
ASCO 2017 AFM26
Ellwanger et al.
Front Oncol. 2017 May 19;7:100. doi: 10.3389/fonc.2017.00100. eCollection 2017.
Kluge et al.
AACR 2017 – AFM24
Weinschenk et al.
AACR 2017 – MHC
Gantke et al.
AACR 2017 – AFM26
Gantke et al.
ASH 2016 – Trispecific Abs
Düll et al.
ASH 2016 – AFM11
Pahl et al.
ASH 2016 – AFM13
Reusch et al.
Clin Cancer Res. 2016 Dec 1;22(23):5829-5838. Epub 2016 May 17.
Ellwanger et al.
AACR 2016